Eco Animal Health

Eco Animal Health has renewed its revolving credit facility with NatWest until 30 June 2031 and maintained availability of up to £10 million. In addition, the £5 million overdraft facility was renewed, bringing total bank facilities to £15 million. The agreement was concluded on more favourable terms; the facility is currently undrawn and is intended to provide liquidity for expansion initiatives. The company is preparing audited annual results for the year ended 31 March 2026 and expects to publish them in mid‑July 2026. » More on de.investing.com

The Eco Animal Health Group has received a positive safety assessment from the USDA for the live vaccine ECOVAXXIN® MG against Mycoplasma gallisepticum. The assessment confirms safety for chickens as well as avian non-target species such as turkeys and quail, and shows no reversion or increase in virulence after passage through chickens. Eco Animal Health plans to file the final approval submission in the U.S. by the end of 2027 and also expects the market launch of another vaccine, ECOVAXXIN® MS, at the end of 2026. » More on de.investing.com

ECO Animal Health will roll out ECOVAXXIN MS across the EU in 2026 and 2027; approval by the European Commission was granted in December 2025. The vaccine protects laying and breeding hens from four weeks of age against Mycoplasma synoviae and is intended to cover markets in the seven largest egg‑producing countries with more than 220 million birds. ECO has signed distribution agreements, will use its existing network and plans an official launch on 30 June–1 July 2026 in Madrid. The company expects an immediate improvement in margins and a material contribution to EBITDA in fiscal year 2027/2028. » More on de.investing.com